Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2025-05-12 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Amendment(s)
Regulatory Filings
2025-05-12 English
General Updates
Regulatory Filings
2025-05-12 English
Outcome of Board Meeting
Regulatory Filings
2025-05-12 English
Outcome of Board meeting held on May 12, 2025
Regulatory Filings
2025-05-12 English
Please find enclosed schedule of investors conference call post declaration of Q4 & FY 2025'' results.
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges about an upcoming conference call to discuss the audited financial results for the quarter and financial year ended March 31, 2025. It includes details about the date, time, mode, and participants of the call. The document does not contain the financial results themselves, nor detailed financial data or analysis. It is an announcement of a conference call following the release of financial results, not the transcript or the results report itself. Therefore, it fits the category of a Call Transcript (CT) announcement or a Regulatory Filing (RNS). However, since it is only an intimation of the conference call and not the transcript, and it is a regulatory announcement pursuant to SEBI regulations, the best fit is Regulatory Filings (RNS). The document length is short (3030 characters), and it is primarily an announcement, not the actual call transcript or financial report.
2025-05-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges about an upcoming conference call to discuss the company's quarterly and full-year financial results for Q4 and FY 2025. It references the declaration of audited financial results but does not contain the financial results themselves or detailed financial data. The document primarily serves as an announcement of the conference call event following the results release. The document length is short (3030 characters), and it is an intimation rather than the actual earnings release or call transcript. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about the conference call and results discussion, not the report or transcript itself.
2025-05-08 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.